Back to Search
Start Over
Treatment of severe psoriasis in children: recommendations of an Italian expert group
- Publication Year :
- 2017
-
Abstract
- This article provides comprehensive recommendations for the systemic treatment of severe pediatric psoriasis based on evidence obtained from a systematic review of the literature and the consensus opinion of expert dermatologists and pediatricians. For each systemic treatment, the grade of recommendation (A, B, C) based on the treatment's approval by the European Medicines Agency for childhood psoriasis and the experts' opinions is discussed. The grade of recommendation for narrow-band-ultraviolet B phototherapy, cyclosporine, and retinoids is C, while that for methotrexate is C/B. The use of adalimumab, etanercept, and ustekinumab has a grade A recommendation. No conventional systemic treatments are approved for pediatric psoriasis. Adalimumab is approved by the European Medicines Agency as a first-line treatment for severe chronic plaque psoriasis in children (≥ 4 years old) and adolescents. Etanercept and ustekinumab are approved as second-line therapy in children ≥ 6 and ≥ 12 years, respectively.A treatment algorithm as well as practical tools (i.e., tabular summaries of differential diagnoses, treatment mechanism of actions, dosing regimens, control parameters) are provided to assist in therapeutic reasoning and decision-making for individual patients. These treatment recommendations are endorsed by major Italian Pediatric and Dermatology Societies. What is Known: • Guidelines for the treatment of severe pediatric psoriasis are lacking and most traditional systemic treatments are not approved for use in young patients. Although there has been decades of experience with some of the traditional agents such as phototherapy, acitretin, and cyclosporine in children, there are no RCTs on their pediatric use while RCTs investigating new biologic agents have been performed. What is New: • In this manuscript, an Italian multidisciplinary team of experts focused on treatment recommendations for severe forms of psoriasis in children based on an up-to-date review of the literature and experts' opinions.
- Subjects :
- medicine.medical_specialty
Consensus
Biologics
Pediatric
Psoriasis
Systemic therapy
Pediatrics, Perinatology and Child Health
Biologic
Anti-Inflammatory Agents
Consensu
Severity of Illness Index
Pediatrics
Etanercept
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Severity of illness
Ustekinumab
medicine
Adalimumab
Humans
Combined Modality Therapy
Dosing
Child
Intensive care medicine
Psoriasi
business.industry
Phototherapy
Perinatology and Child Health
medicine.disease
Dermatology
Settore MED/38
Italy
030220 oncology & carcinogenesis
Anti-Inflammatory Agents Child Combined Modality Therapy Dermatologic Agents Humans Italy Phototherapy Psoriasis Severity of Illness Index
Dermatologic Agents
business
Settore MED/35 - MALATTIE CUTANEE E VENEREE
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....42a1d07da3d442895999ee527f108d01